Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Enables protein heterodimerization activity. Involved in regulation of skeletal muscle fiber development. Acts upstream of or within with a positive effect on myoblast fusion. Acts upstream of or within hematopoietic or lymphoid organ development. Predicted to be located in bicellular tight junction and membrane. Predicted to be part of protein complex involved in cell adhesion. Predicted to be active in cell surface; plasma membrane; and tight junction. Is expressed in several structures, including blood vessel; musculature system; myoblast; nervous system; and pectoral fin bud. Human ortholog(s) of this gene implicated in basal ganglia calcification. Orthologous to human JAM2 (junctional adhesion molecule 2). [provided by Alliance of Genome Resources, Feb 2025]